Biotech Values

[DewDiligence]

There is…an economic difference between biosimilars and interchangeables. Doctors hesitate to prescribe generic biologicals which are not declared as interchangeable (look at europe). Biosimilars will not be a economic success.

Certainly, interchangeable biogenerics are a better business proposition than non-substitutable biosimilars, which is why MNTA is focusing on the former. However, I think it’s premature to say that non-substitutable biosimilars are destined to be commercial flops. The weak sales of these products to date in Europe can be attributed to the product mix, which consists of EPO, G-CSF, and hGH. When biosimilar mAbs finally reach the market, the sales will be substantial larger than the sales of the current crop of biosimilars, IMO.

In other respects, I agree with your post. Regards, Dew